D. Gonzalez, L. Fearfield, P. Nathan, P. Tanière, A. Wallace, E. Brown, C. Harwood, J. Marsden and S. Whittaker BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel British Journal of Dermatology 168
What’s already known about this topic?
Mutations in the BRAF gene have been identified as key drivers of melanoma cells and are found in around 50% of cutaneous melanomas.
Vemurafenib (Zelboraf®) is the first licensed inhibitor of mutated BRAF and offers a new first-line option for patients with unresectable or metastatic melanoma who harbour BRAF mutations.
Vemurafenib was developed in conjunction with a companion diagnostic, the cobas® 4800 BRAF V600 Mutation Test.
What does this study add?
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf